Sign Up Today and Learn More About Aro Biotherapeutics Stock
Invest in or calculate the value of your shares in Aro Biotherapeutics or other pre-IPO companies through EquityZen's platform.
Aro Biotherapeutics Stock (AROB)
Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.
About Aro Biotherapeutics Stock
Founded
2017
Headquarters
Philadelphia, PA, US
Industries
Science and Engineering, Health Care, Biotechnology
Aro Biotherapeutics Press Mentions
Stay in the know about the latest news on Aro Biotherapeutics
Cd71 binding fibronectin type iii domains
patents • Apr 02, 2025
Fn3 domain-sirna conjugates and uses thereof
patents • Apr 02, 2025
Philadelphia biotech firm backed by more than $130M names new CEO
bizjournals • Feb 11, 2025
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
biospace • Feb 11, 2025
Aro Biotherapeutics Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
citybiz • Feb 11, 2025
Aro Biotherapeutics Management
Leadership team at Aro Biotherapeutics
Co-founder and Chief Scientific Officer
Karyn O’Neil
Co-founder, President and Chief Executive Officer
Susan Dillon
Join now and verify your accreditation status to gain access to:
- Aro Biotherapeutics Current Valuation
- Aro Biotherapeutics Stock Price
- Aro Biotherapeutics Management
- Available deals in Aro Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Aro Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Aro Biotherapeutics Revenue and Financials
- Aro Biotherapeutics Highlights
- Aro Biotherapeutics Business Model
- Aro Biotherapeutics Risk Factors
- Aro Biotherapeutics Research Report from SACRA Research
Trading Aro Biotherapeutics Stock
How to invest in Aro Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Aro Biotherapeutics through EquityZen funds. These investments are made available by existing Aro Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Aro Biotherapeutics stock?
Shareholders can sell their Aro Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
